



Commonwealth
of Australia

Letters patent

Patents Act 1990

No.
692469

Nexograft

STANDARD PATENT

I, Bruce Ian Murray, Commissioner of Patents, grant a Standard Patent with the following particulars:

Name and Address of Patentee:

NeXstar Pharmaceuticals, Inc, Suite 200 2860 Wilderness Place Boulder CO 80301 United States of America

Names of Actual Inventors: Larry Gold; Wolfgang Pieken; Diane Tasset; Nebojsa Janjic; Gary P. Kirschenheuter; Barry Polisky; Sumedha Jayasena; Greg Biesecker; Drew Smith and Robert D Jenison

Title of Invention: Nucleic acid ligands and improved methods for producing the same

Application Number: 76865/94

Term of Letters Patent: Twenty years commencing on 8 September 1994

Priority Details:

Number	Date	Filed with
117991	8 September 1993	UNITED STATES OF AMERICA
134028	7 October 1993	UNITED STATES OF AMERICA
199507	22 February 1994	UNITED STATES OF AMERICA
233012	25 April 1994	UNITED STATES OF AMERICA
234997	28 April 1994	UNITED STATES OF AMERICA

Dated this 5 day of November 1998



B.I. Murray

B.I. MURRAY
COMMISSIONER OF PATENTS

(12) PATENT ABRIDGMENT (11) Document No. AU-B-76865/94
 (19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 692469

- (54) Title
 NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME
- (51)⁶ International Patent Classification(s)
 C12Q 001/68
- (21) Application No. : 76865/94 (22) Application Date : 08.09.94
- (87) PCT Publication Number : WO95/07364
- (30) Priority Data
- | | | |
|-------------|-----------|-----------------------------|
| (31) Number | (32) Date | (33) Country |
| 117991 | 08.09.93 | US UNITED STATES OF AMERICA |
| 134028 | 07.10.93 | US UNITED STATES OF AMERICA |
| 199507 | 22.02.94 | US UNITED STATES OF AMERICA |
| 233012 | 25.04.94 | US UNITED STATES OF AMERICA |
| 234997 | 28.04.94 | US UNITED STATES OF AMERICA |
- (43) Publication Date : 27.03.95
- (44) Publication Date of Accepted Application : 11.06.98
- (71) Applicant(s)
 NEXSTAR PHARMACEUTICALS, INC
- (72) Inventor(s)
 LARRY GOLD; WOLFGANG PIEKEN; DIANE TASSET; NEBOJSA JANJIC; GARY P. KIRSCHENHEUTER; BARRY POLISKY; SUMEDHA JAYASENA; GREG BIESECKER; DREW SMITH; ROBERT D JENISON
- (74) Attorney or Agent
 DAVIES COLLISON CAVE , 1 Little Collins Street, MELBOURNE VIC 3000
- (56) Prior Art Documents
 AU 82061/91
 US 5476766

(57) Described herein are high affinity nucleic acid ligands to vascular endothelial growth factor (VEGF), human neutrophil elastase, theophylline, caffeine and thrombin. The method utilized herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by EXponential enrichment. Further described herein are methods for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed "counter-SELEX", methods for combining nucleic acids with other functional units for generation of high affinity ligands, termed "blended SELEX" and methods for preparing modified oligonucleotides capable of binding target molecules with high affinity. Specifically disclosed herein are high-affinity nucleic acid ligands to VEGF, elastase, caffeine and theophylline, including single-stranded RNA and DNA ligands, single-stranded RNA ligands

(10) 692469

able to discriminate between theophylline and caffeine and RNA ligands to thrombin containing 2'-NH₂-modifications.

The modified oligonucleotides of the present invention contain one or more modified nucleotide bases, which include 5-X and/or 2'-Y substitutions in pyrimidine bases and 8-X and/or 2'Y substitutions in purine bases.

Claim

1. A method for identifying nucleic acid ligands to a target, comprising:
 - a) contacting a candidate mixture of modified nucleic acids containing nucleotides chemically modified at the ribose and/or phosphate and/or base positions, but excluding modifications at the cytosine exocyclic amino, 5-bromo substitution of uracil and methylation, with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
 - b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
 - c) amplifying the increased affinity nucleic acids *in vitro* to yield a ligand-enriched mixture of nucleic acids.
8. A purified and isolated non-naturally occurring nucleic acid ligand to vascular endothelial growth factor (VEGF), elastase, thrombin, caffeine or theophylline.
18. A method of identifying nucleic acid ligand(s) to a target molecule, comprising:
 - a) contacting a candidate mixture of nucleic acids with the target molecule, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the mixture;
 - b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
 - c) contacting the increased affinity nucleic acids with one or more non-target molecules, and removing nucleic acids with affinity to the non-target molecule(s); and
 - d) amplifying the nucleic acids with specific affinity to the target molecule, to yield a nucleic acid product enriched for nucleic acid sequences with higher affinity and specificity for binding to the target molecule relative to the corresponding method in which step (c) is omitted.